| Literature DB >> 34993638 |
Sajad Rashidi1, Celia Fernández-Rubio2, Reza Mansouri3, Mohammad Ali-Hassanzadeh4, Esmaeel Ghani5, Mohammadreza Karimazar1, Raúl Manzano-Román6, Paul Nguewa7.
Abstract
The current drug treatments against protozoan parasitic diseases including Chagas, malaria, leishmaniasis, and toxoplasmosis represent good examples of drug resistance mechanisms and have shown diverse side effects. Therefore, the identification of novel therapeutic strategies and drug compounds against such life-threatening diseases is urgent. According to the successful usage of selenium (Se) compounds-based therapy against some diseases, this therapeutic strategy has been recently further underlined against these parasitic diseases by targeting different parasite´s essential pathways. On the other hand, due to the important functions played by parasite selenoproteins in their biology (such as modulating the host immune response), they can be also considered as a novel therapeutic strategy by designing specific inhibitors against these important proteins. In addition, the immunomodulatory potentiality of these compounds to trigger T helper type 1 (Th1) cells and cytokine-mediated immune response for the substantial induction of proinflammatory cytokines, thus, Se, selenoproteins, and parasite selenoproteins could be further investigated to find possible vaccine antigens. Herein, we collect and present the results of some studies regarding Se-based therapy against protozoan parasitic diseases and highlight relevant information and some viewpoints that might be insightful to advance toward more effective studies in the future.Entities:
Keywords: Protozoan parasitic diseases; Se supplementation; Se-nanoparticles; Selenium; Therapy
Mesh:
Substances:
Year: 2022 PMID: 34993638 PMCID: PMC8735723 DOI: 10.1007/s00436-021-07400-8
Source DB: PubMed Journal: Parasitol Res ISSN: 0932-0113 Impact factor: 2.289
Fig. 1The regulatory effects of Se and selenoproteins on the immune cells
Fig. 2Bioinformatics tools to discovery/analyze selenoproteins genome
In vitro and in vivo effects of Se/selenocompounds-based therapy against protozoan parasites
| Protozoan parasites | Se compounds | Efficacy | Possible mechanism of action | References | |
|---|---|---|---|---|---|
| In vitro | In vivo | ||||
| Niosomal combination of Se coupled with Amphotericin B, and Glucantime | Leishmanicida (promastigote and amastigote) | Decreasing the levels of IL-10 and increasing IL-12 (as Th1 activator) | Increased expression of metacaspase in promastigotes (inducing apoptosis) | (Mostafavi et al. | |
| Methylseleno-Imidocarbamates | Inducing nitric oxide production, potent effect on the cell cycle (inducing arrest in G1) | (Fernández-Rubio et al. | |||
| Isoselenocyanate derivatives | Reduced expression of | ||||
Naphthalamide isoselenocyanate-6 (NISC-6) | Leishmanicida (amastigote) | (Fernández-Rubio et al. | |||
Selenocyanate and diselenide derivatives containing amide moiety | Leishmanicida (amastigote) | Targeting parasite trypanothione reductase | (Baquedano et al. | ||
| Heteroaryl Selenocyanates and Diselenides | |||||
| Selenourea derivatives of Diselenides | (Díaz et al. | ||||
| 3,5-Dimethyl-4-isoxazoyl selenocyanate (a compound with good intestinal permeability) | Reducing parasite load in liver (99.2%), spleen (91.7%) and bone marrow (61.4%) | (Alcolea et al. | |||
| Organoselenium bearing sulfonamide moiety | Leishmanicida (amastigote) | Parasite Carbonic Anhydrase inhibitors | (Al-Tamimi et al. | ||
| Organic Se compounds | (Cabrera et al. | ||||
| Se | Leishmanicida (promastigote and amastigote) | Inhibiting Fe-SOD | (Martín-Montes et al. | ||
| SeNPs | Reducing the leishmanial-lesions size | Inducing apoptosis in promastigotes | (Beheshti et al. | ||
| Se-containing analogues of WC-9 | Activity against tachyzoites | (Chao et al. | |||
| Sulfamethoxazole/Trimethoprim supplemented with diphenyl diselenide and sodium selenite | Reducing IFN-γ and increasing IL-10 (preventing excessive tissue damage) | Protective mechanism through the balance between pro- and anti-inflammatory cytokines | (Barbosa et al. | ||
| Diphenyl diselenide | Decreasing thiobarbituric acid reactive species (TBARS) levels in infected mice and increasing the Glutathione S transferase (GST) activity in the brain | Protective action as antioxidant | (Machado et al. | ||
| SeNPs | Increasing mRNA levels of inflammatory cytokines ( | (Keyhani et al. | |||
| Same effect and more cytotoxicity compared to Metronidazole in killing of cysts | (Malekifard et al. | ||||
| Decreasing the numbers of meronts, gamonts, and developing oocysts, regulating the expression of pro-inflammatory cytokines ( | Reversing the disturbance of the redox status in infected cells (antioxidant property), reducing the Bax and caspase-3 expression (anti-apoptotic property) | (Alkhudhayri et al. | |||
| Selenocompounds (derivative 26), Selenocyanate and Diselenide derivatives | Trypanocidal | Mitochondrial membrane depolarization, inhibition of nucleic acid levels, Fe-SOD enzyme inhibition (cell death induction by bioenergetics collapse) | (Martín-Escolano et al. | ||
| Selenocyanate derivatives (analogues of WC-9) | Trypanocidal | Inhibitor of parasite squalene synthase | (Chao et al. | ||
| Selenides-1,2,3-triazoles | A possible effective compound (further in vitro and in vivo studies are needed) | (Brasil et al. | |||
| Se + Zinc | Increasing protection against cellular damage | Regulating lipid peroxidation and endogenous antioxidant enzymes | (Sheneni et al. | ||
| Diglycosyl diselenides | Trypanocidal | Altering glucose metabolism in parasites, interference with the redox homeostasis | (Franco et al. | ||
| Se | Decreasing number of oocysts in feces and a longer survival time in infected mice | Se-compounds reactions with thiols (glutathione) and enhanced levels of superoxide and hydrogen peroxide | (Huang and Yang | ||